Pranita D Tamma1, Jennifer H Han2, Clare Rock3, Anthony D Harris3, Ebbing Lautenbach2, Alice J Hsu4, Edina Avdic4, Sara E Cosgrove5. 1. Department of Pediatrics, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Medicine, Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia. 3. Department of Epidemiology and Public Health, University of Maryland School of Medicine. 4. Department of Pharmacy, Johns Hopkins Hospital. 5. Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: The effectiveness of piperacillin-tazobactam (PTZ) for the treatment of extended-spectrum β-lactamase (ESBL) bacteremia is controversial. We compared 14-day mortality of PTZ vs carbapenems as empiric therapy in a cohort of patients with ESBL bacteremia who all received definitive therapy with a carbapenem. METHODS: Patients hospitalized between January 2007 and April 2014 with monomicrobial ESBL bacteremia were included. A decrease of >3 doubling dilutions in the minimum inhibitory concentration for third-generation cephalosporins tested in combination with 4 µg/mL of clavulanic acid was used to confirm ESBL status. The primary exposure was empiric therapy, defined as antibiotic therapy administered to a patient before ESBL status was known. Patients were excluded if they did not receive a carbapenem after ESBL production was identified. The primary outcome was time to death from the first day of bacteremia. Propensity scores using inverse probability of exposure weighting (IPW) were used to estimate the probability that a patient would receive PTZ vs carbapenems empirically. We calculated overall hazard ratios for mortality censored at 14 days using Cox proportional hazards models on an IPW-adjusted cohort. RESULTS: A total of 331 unique patients with ESBL bacteremia were identified. One hundred three (48%) patients received PTZ empirically and 110 (52%) received carbapenems empirically. The adjusted risk of death was 1.92 times higher for patients receiving empiric PTZ compared with empiric carbapenem therapy (95% confidence interval, 1.07-3.45). CONCLUSIONS: PTZ appears inferior to carbapenems for the treatment of ESBL bacteremia. For patients at high risk of invasive ESBL infections, early carbapenem therapy should be considered. Our findings should not be extended to β-lactam/β-lactamase inhibitor combinations in development, as limited clinical data are available for these agents.
BACKGROUND: The effectiveness of piperacillin-tazobactam (PTZ) for the treatment of extended-spectrum β-lactamase (ESBL) bacteremia is controversial. We compared 14-day mortality of PTZ vs carbapenems as empiric therapy in a cohort of patients with ESBL bacteremia who all received definitive therapy with a carbapenem. METHODS:Patients hospitalized between January 2007 and April 2014 with monomicrobial ESBL bacteremia were included. A decrease of >3 doubling dilutions in the minimum inhibitory concentration for third-generation cephalosporins tested in combination with 4 µg/mL of clavulanic acid was used to confirm ESBL status. The primary exposure was empiric therapy, defined as antibiotic therapy administered to a patient before ESBL status was known. Patients were excluded if they did not receive a carbapenem after ESBL production was identified. The primary outcome was time to death from the first day of bacteremia. Propensity scores using inverse probability of exposure weighting (IPW) were used to estimate the probability that a patient would receive PTZ vs carbapenems empirically. We calculated overall hazard ratios for mortality censored at 14 days using Cox proportional hazards models on an IPW-adjusted cohort. RESULTS: A total of 331 unique patients with ESBL bacteremia were identified. One hundred three (48%) patients received PTZ empirically and 110 (52%) received carbapenems empirically. The adjusted risk of death was 1.92 times higher for patients receiving empiric PTZ compared with empiric carbapenem therapy (95% confidence interval, 1.07-3.45). CONCLUSIONS:PTZ appears inferior to carbapenems for the treatment of ESBL bacteremia. For patients at high risk of invasive ESBL infections, early carbapenem therapy should be considered. Our findings should not be extended to β-lactam/β-lactamase inhibitor combinations in development, as limited clinical data are available for these agents.
Authors: Daryl J Hoban; Samuel K Bouchillon; Stephen P Hawser; Robert E Badal; Vincent J Labombardi; Joseph DiPersio Journal: Antimicrob Agents Chemother Date: 2010-05-10 Impact factor: 5.191
Authors: Jennifer H Han; Irving Nachamkin; Theoklis E Zaoutis; Susan E Coffin; Darren R Linkin; Neil O Fishman; Mark G Weiner; Baofeng Hu; Pam Tolomeo; Ebbing Lautenbach Journal: Infect Control Hosp Epidemiol Date: 2012-10-23 Impact factor: 3.254
Authors: Yen-Hsu Chen; Po-Ren Hsueh; Robert E Badal; Stephen P Hawser; Daryl J Hoban; Samuel K Bouchillon; Yuxing Ni; David L Paterson Journal: J Infect Date: 2011-03-05 Impact factor: 6.072
Authors: Michael N Dudley; Paul G Ambrose; Sujata M Bhavnani; William A Craig; Mary Jane Ferraro; Ronald N Jones Journal: Clin Infect Dis Date: 2013-01-18 Impact factor: 9.079
Authors: Gopi Patel; Shirish Huprikar; Stephanie H Factor; Stephen G Jenkins; David P Calfee Journal: Infect Control Hosp Epidemiol Date: 2008-12 Impact factor: 3.254
Authors: Pranita D Tamma; Sonya C T Girdwood; Ravindra Gopaul; Tsigereda Tekle; Ava A Roberts; Anthony D Harris; Sara E Cosgrove; Karen C Carroll Journal: Clin Infect Dis Date: 2013-06-11 Impact factor: 9.079
Authors: Grace E Benanti; Anne Rain T Brown; Terri Lynn Shigle; Jeffrey J Tarrand; Micah M Bhatti; Patrick M McDaneld; Samuel A Shelburne; Samuel L Aitken Journal: Antimicrob Agents Chemother Date: 2019-01-29 Impact factor: 5.191
Authors: Katherine E Goodman; Justin Lessler; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Jennifer H Han; Aaron M Milstone; Colin J Massey; Pranita D Tamma Journal: Clin Infect Dis Date: 2016-06-28 Impact factor: 9.079
Authors: Michael J Satlin; Kalyan D Chavda; Thomas M Baker; Liang Chen; Elena Shashkina; Rosemary Soave; Catherine B Small; Samantha E Jacobs; Tsiporah B Shore; Koen van Besien; Lars F Westblade; Audrey N Schuetz; Vance G Fowler; Stephen G Jenkins; Thomas J Walsh; Barry N Kreiswirth Journal: Clin Infect Dis Date: 2018-11-13 Impact factor: 9.079
Authors: Henrietta Abodakpi; Kai-Tai Chang; Song Gao; Ana María Sánchez-Díaz; Rafael Cantón; Vincent H Tam Journal: Antimicrob Agents Chemother Date: 2019-01-29 Impact factor: 5.191
Authors: D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2019-10 Impact factor: 1.041
Authors: Heather R Cross; Anthony Harris; Rebekka M Arias; Henry F Chip Chambers; Vance G Fowler Journal: Clin Infect Dis Date: 2017-03-15 Impact factor: 9.079